If you missed a dose of Biktarvy, how long ago matters. The European label draws the line at 18 hours: inside that window, take it. Past it, skip it and resume your usual schedule. The US label gives no rule at all. Confirm with your prescriber.
That gap between two labels for the same tablet is worth knowing about. It explains why searching for this is so frustrating.
Your US label does not answer this. The European one does.
Biktarvy is made by one company and sold in both places. Yet the two regulators documented the missed dose question very differently.
The FDA prescribing information covers dosing, interactions, side effects, and a boxed warning. It contains no missed dose instruction. Not a vague one, none at all.
The European Medicines Agency product information has a section headed "Missed doses" and states: "If the patient misses a dose of Biktarvy within 18 hours of the time it is usually taken, the patient should take Biktarvy as soon as possible and resume the normal dosing schedule. If a patient misses a dose of Biktarvy by more than 18 hours, the patient should not take the missed dose and simply resume the usual dosing schedule."
The patient leaflet in the same document repeats it in plainer language for readers.
| Question | FDA label (US) | EMA label (EU) |
|---|---|---|
| What if I miss a dose? | No instruction given | Within 18 hours, take it. More than 18 hours, skip it. |
| What if I throw up after a dose? | No instruction given | Under 1 hour, take another. Over 1 hour, no extra dose. |
| What about stopping? | Boxed warning on hepatitis B flare after discontinuation | "Stopping Biktarvy can seriously affect how future treatment works." |
Neither label is wrong. They follow different documentation conventions. The practical result is what matters: a US reader can read their own label end to end and not find the answer they came for.
Where the 18-hour number probably comes from
An 18-hour cutoff looks random until you look at how long the drug lasts.
Biktarvy combines three medicines, and the FDA label lists a median elimination half-life for each: bictegravir at 17.3 hours, emtricitabine at 10.4 hours, and tenofovir alafenamide at 0.51 hours. Bictegravir is the integrase inhibitor, the component doing the heavy lifting against the virus.
Its half-life is 17.3 hours. The European cutoff is 18.
Neither label says the two numbers are connected, so treat that as an observation rather than the official reasoning. Still, it gives you a way to think about the window instead of learning a number by heart. It is roughly one half-life of the main component. Past that, a catch-up dose starts to crowd the next scheduled one.
All of this assumes you know when your last dose actually was. If you cannot pin that down, the window is not something to estimate. Estimating is the part that goes wrong, because a guess of "probably within 18 hours" is how a dose the label says to skip gets taken anyway. Treat an unknown last dose as a question for your prescriber or pharmacist, and lean on whatever record you have rather than memory.
The rule for throwing up is separate
This one almost never appears on US pages, and it is a different problem from forgetting.
The European label states: "If the patient vomits within 1 hour of taking Biktarvy another tablet should be taken. If a patient vomits more than 1 hour after taking Biktarvy they do not need to take another dose of Biktarvy until the next regularly scheduled dose."
One hour, not eighteen. The logic is about absorption rather than timing, and the same idea shows up across many medications. We cover the general version in our guide on what to do after throwing up medication.
What both labels agree on: do not stop on your own
The two regulators document the missed dose differently. On stopping, they say the same thing in different words, and this is the part that matters most.
The US boxed warning states that "severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and HBV who have discontinued" these medicines, and that this "may occur with discontinuation of BIKTARVY." A boxed warning is the strongest warning the FDA uses.
The European patient leaflet is blunter: "Stopping Biktarvy can seriously affect how future treatment works." It adds that virus levels can rise even after a short interruption, which can make treatment harder.
The leaflet flags hepatitis B separately. For some patients with advanced liver disease or cirrhosis, it says stopping treatment "may lead to worsening of your hepatitis, which may be life-threatening."
One missed dose is not stopping. But a run of them becomes stopping without anyone deciding to. That is why a slipping routine is worth mentioning to your prescriber, rather than saving it for the next appointment.
What one missed dose actually does
Here is the part that usually gets left out, and it is more reassuring than most pages let on.
Researchers followed 281 adults on this exact combination for 343 patient-years and measured how much imperfect adherence it tolerated. That 2022 study in the Journal of the International Association of Providers of AIDS Care found that a proportion of days covered as low as 70 percent was enough to reach and hold virologic suppression.
Read that closely before you relax too much. Median adherence in that same group was 98 percent. The finding describes what the regimen tolerated in a well-controlled cohort. It is not a target to aim at, and the researchers were not recommending 70 percent.
The wider evidence points the same direction. A meta-analysis in Medicine pooling 43 studies and 27,905 participants found that the familiar 95 percent adherence threshold is not the sharp cliff it is often presented as. The authors concluded that the real threshold is "wider than the commonly used cut-off point."
The honest summary: one late or missed dose is not a crisis, and modern regimens are more forgiving than the ones these rules were originally written for. Consistency still matters, and your prescriber is the person to talk to about your own numbers.
How Pillo helps with a once-daily tablet
Once-daily medications are easy in theory and slippery in practice. The dose happens at the same time every day, which means it stops being a decision and becomes background. Background things are exactly what you later cannot remember doing.
Pillo keeps the alarm going until you confirm the dose, so it does not get silently swiped away during a busy morning. Each confirmation becomes a record, which turns "did I take it today?" into something you can check instead of reconstruct. That record also gives you an accurate answer when a clinician asks how your last few weeks have gone.
If an 18-hour window is part of your plan, knowing the exact time of your last confirmed dose is the whole ballgame. Guessing at it is what makes the question hard.
Two related guides: what to do when you cannot remember if you took your medication, and adjusting medication across time zones. The second matters here, because an 18-hour window and a long flight interact in ways that are easy to get wrong.
Most daily drugs never get a number like this
The general advice most people have absorbed is to take a missed dose when they remember unless it is nearly time for the next one. We describe that default in our guide to what to do when you miss a dose of medication.
Biktarvy is unusual in that a regulator put a number on it. Most drugs do not get that. A missed dose of tacrolimus and a missed dose of Keppra each carry their own logic, with no published hour threshold. A missed dose of pyridostigmine has no instruction in any label, for a different reason again.
FAQ
How long after my usual time can I still take Biktarvy?
The European label sets the boundary at 18 hours. A dose noticed inside that window should be taken as soon as possible. One noticed 18 hours or more after the usual time should be skipped. The FDA label gives no equivalent rule, so confirm with your prescriber which guidance applies to you.
Why does the FDA label not say anything about missed doses?
US and EU labels follow different documentation conventions, and missed dose instructions are far more common in European product information. The absence is not a signal that missing a dose does not matter. It just means the answer is not in that document.
Should I take two Biktarvy tablets to catch up?
No. Neither regulator describes doubling up. For a dose past the window, the European label says to skip it and resume the usual schedule. If you have already taken extra, tell your prescriber or pharmacist.
What if I threw up right after taking Biktarvy?
That is treated separately from forgetting. The European label says a patient who vomits within 1 hour of the dose should take another tablet, and one who vomits more than 1 hour after does not need another until the next scheduled dose.
Does missing one dose mean the medicine stops working?
One missed dose is not the same as stopping. In a 2022 cohort of 281 adults on this regimen, virologic suppression was maintained at adherence levels below perfect. What both labels warn about is stopping, with the FDA carrying a boxed warning about hepatitis B flares after discontinuation.
What if I do not know when I took my last dose?
Then the 18-hour window is not something you can apply, because it depends entirely on that starting time. Ask your prescriber or pharmacist rather than estimating. Keeping a dose record going forward turns this from a memory problem into something you can check in a second.
What if I keep missing doses?
Tell your prescriber rather than waiting for your next scheduled visit. A pattern of missed doses is a different conversation from a single one, and it is a practical problem with practical fixes, not something to be judged for.
This article provides general information about medication management and is not a substitute for professional medical advice. Always consult your doctor or pharmacist before making changes to your medication schedule.
